Eiger BioPharmaceuticals's total liabilities is $53M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (December 2023), EIGR shows a total liabilities of $53M. That compares with $65M in the prior-year period — down 17.8% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, EIGR's total liabilities is now $53M (was $65M) — a 17.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Eiger BioPharmaceuticals is outperforming or lagging.
Tracking EIGR's total liabilities over time shows whether Eiger BioPharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $53M That compares with $65M in the prior-year period — down 17.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total liabilities page, Stockcircle has Eiger BioPharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $53M) with ownership activity and broader fundamentals.
Eiger BioPharmaceuticals's total liabilities is $53M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.